Eiger sells gene therapy candidate Mydicar to Theragene for $3.1M in cash and stock – Seeking Alpha
Pharmaceutical Processing |
Eiger sells gene therapy candidate Mydicar to Theragene for $3.1M in cash and stock
Seeking Alpha Mydicar is a cardiovascular gene therapy product that employs an adeno-associated virus (AAV) to deliver a certain protein to cardiac cells. Celladon was developing it to treat heart failure but a mid-stage study failed. It merged with Eiger in March 2016. Eiger BioPharma off-loads non-core asset for $3.1 million |
